Experimental Insulin Like Growth Factor Receptor Inhibitor Reduced Pancreatic Cancer Growth

Researchers at Amgen are testing a fully human monoclonal antibody that inhibits the activity of insulin-like growth factors (IGF-1 and IGF-2) and appears to reduce pancreatic cancer cells in early testing, according to a report in Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research. Pancreatic cancer is one of the deadliest cancers, and less than 4 percent of the 200,000 patients diagnosed annually live more than five years.

More: continued here

Filed under: Clinical Trials on April 15th, 2009